Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULAR, INTRAVENOUSGeneric

ROCEPHIN

CEFTRIAXONE SODIUM

Standard Dose
EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ROCEPHIN is listed in Drugs@FDA under application 050585 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFTRIAXONE SODIUM Form and strength INJECTABLE;INTRAMUSCULAR, INTRAVENOUS - EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HOFFMANN LA ROCHE Submission history Latest submission status date: 2018-07-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview ROCEPHIN is listed in Drugs@FDA under application 050585 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFTRIAXONE SODIUM Form and strength INJECTABLE;INTRAMUSCULAR, INTRAVENOUS - EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HOFFMANN LA ROCHE Submission history Latest submission status date: 2018-07-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ROCEPHIN (CEFTRIAXONE SODIUM) | Drug Monograph | MedicHelpline